Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2007

View Archived Issues

Investigational prokinetic 5-HT4 agonist advancing through the pipeline

Support for activation of SIRT1 as a novel approach to type 2 diabetes

Cadence increases enrollment of phase III trial of Omigard for LCSI reduction

Quigley Pharma initiates clinical trial of QR-449 for metabolic syndrome

Positive results for Phytopharm's liquid formulation of Myogane

Elan announces second quarter 2007 results

Positive results for Biolex's phase IIa trial of Locteron for hepatitis C

Ranbaxy claims new drugs for respiratory disorders

New treatment options for dermatological disorders divulged in recent patent

Recent patent literature discloses new antiobesity drugs

EvaMist approved by the FDA

Symposium features Sirtex's SIR-Spheres for colorectal liver metastases

Anadys and Novartis discontinue development of ANA-975 for HCV

Abbott voluntarily withdraws E.U. marketing authorization for Trudexa

Targacept initiates phase I clinical trial of TC-5619

ReNeuron acquires business assets from AmCyte

Threshold begins phase I trial of TH-302 for solid tumors

Regulatory update on satraplatin

GSK and Targacept to codevelop novel NNRs targeting therapeutics

Toyama receives marketing approval for Geninax in Japan

Clinical evaluation to commence for a new agent for hyperlipidemia

Eisai to begin trial to determine MTD of E-7107 in cancer patients

Elixir presents data on ghrelin- and sirtuin-based programs for metabolic diseases

Fludarabine plus cyclophosphamide for the treatment of CLL

First small-molecule HIV-1 Tat-PP-1 inhibitors designed to inhibit HIV-1 transcription described

Comparison of different formulations of mycophenolic acid in IgA nephritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...